MeSH term
Frequency | Condition_Probility | Adult | 13 | 0.0 |
Comparative Study | 9 | 0.0 |
Humans | 90 | 0.0 |
Animals | 45 | 0.0 |
Calcium/metabolism | 2 | 0.0 |
Cell Line | 9 | 0.0 |
*Gene Expression | 2 | 0.0 |
Gene Expression Profiling | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 86 | 0.0 |
Blotting, Northern | 9 | 0.0 |
Blotting, Western | 6 | 0.0 |
*Cell Cycle Proteins | 5 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Protein Binding | 7 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Rats | 16 | 0.0 |
S100 Proteins/*metabolism | 12 | 21.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Aged | 16 | 0.0 |
Disease-Free Survival | 4 | 0.0 |
Female | 32 | 0.0 |
Gene Expression Regulation, Neoplastic | 10 | 0.0 |
Immunohistochemistry | 24 | 0.0 |
Middle Aged | 16 | 0.0 |
Multivariate Analysis | 5 | 0.0 |
Neoplasm Staging | 8 | 0.0 |
Predictive Value of Tests | 7 | 0.0 |
Prognosis | 14 | 0.0 |
Protein p53/analysis | 3 | 1.0 |
Receptor, erbB-2/analysis | 3 | 3.0 |
Risk Factors | 4 | 0.0 |
S100 Proteins/*analysis | 9 | 19.0 |
Tumor Markers, Biological/*analysis | 4 | 0.0 |
Amino Acid Sequence | 10 | 0.0 |
Mice | 23 | 0.0 |
Molecular Sequence Data | 13 | 0.0 |
*Neoplasm Metastasis | 2 | 2.0 |
Tumor Cells, Cultured | 35 | 0.0 |
Male | 14 | 0.0 |
S100 Proteins/*biosynthesis | 4 | 36.0 |
Time Factors | 3 | 0.0 |
In Situ Hybridization | 4 | 0.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Reference Values | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 13 | 0.0 |
S100 Proteins/*analysis/genetics | 5 | 100.0 |
Transcription, Genetic | 5 | 0.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Survival Rate | 4 | 0.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
*Disease Models, Animal | 2 | 0.0 |
Neoplasm Metastasis | 16 | 1.0 |
Neoplasm Transplantation | 3 | 0.0 |
S100 Proteins/genetics/*metabolism | 4 | 22.0 |
Transfection | 9 | 0.0 |
Binding Sites | 5 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Phosphorylation | 3 | 0.0 |
Protein Conformation | 4 | 0.0 |
Recombinant Proteins/metabolism | 6 | 0.0 |
S100 Proteins/*chemistry/*metabolism | 4 | 50.0 |
Carcinoma, Pancreatic Ductal/*genetics/metabolism | 3 | 75.0 |
Mutation | 3 | 0.0 |
Pancreatic Neoplasms/*genetics/metabolism/pathology | 2 | 10.0 |
Reproducibility of Results | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 14 | 0.0 |
DNA Methylation | 2 | 0.0 |
S100 Proteins/*genetics/*metabolism | 2 | 66.0 |
S100 Proteins/*chemistry | 3 | 25.0 |
Cells, Cultured | 7 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Rats, Wistar | 3 | 0.0 |
S100 Proteins/*pharmacology | 3 | 75.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Kinetics | 4 | 0.0 |
Phenotype | 4 | 0.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Calcium-Binding Proteins/metabolism | 2 | 2.0 |
Neoplasm Invasiveness/*genetics | 2 | 5.0 |
RNA, Messenger/analysis | 6 | 0.0 |
S100 Proteins/*genetics | 8 | 40.0 |
Cell Cycle | 3 | 0.0 |
Cell Division | 3 | 0.0 |
Enzyme Activation | 2 | 0.0 |
Down-Regulation | 2 | 0.0 |
Epithelium/metabolism | 2 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Up-Regulation | 2 | 0.0 |
S100 Proteins/*biosynthesis/genetics | 2 | 22.0 |
*Gene Expression Profiling | 4 | 0.0 |
Neoplasm Metastasis/*genetics/pathology | 2 | 20.0 |
Oligonucleotide Array Sequence Analysis | 7 | 0.0 |
Rats, Sprague-Dawley | 4 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Dimerization | 3 | 0.0 |
Models, Molecular | 3 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Aged, 80 and over | 9 | 0.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Lymphatic Metastasis | 3 | 0.0 |
Receptors, Estrogen/analysis | 3 | 0.0 |
Receptors, Progesterone/analysis | 2 | 0.0 |
Survival Analysis | 3 | 0.0 |
Cell Division/genetics | 2 | 0.0 |
Gene Expression Regulation/drug effects | 3 | 0.0 |
*Microtubule Proteins | 2 | 6.0 |
*Gene Expression Regulation, Neoplastic | 5 | 0.0 |
Ki-67 Antigen/analysis | 2 | 0.0 |
Neoplasm Invasiveness | 10 | 0.0 |
Astrocytes/cytology/*metabolism | 2 | 11.0 |
Sequence Alignment | 2 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Adolescent | 2 | 0.0 |
Rabbits | 4 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
S100 Proteins/biosynthesis/*genetics | 2 | 50.0 |
Calcium-Binding Proteins/*genetics | 4 | 4.0 |
*Gene Expression Regulation | 3 | 0.0 |
S100 Proteins/analysis/*genetics | 2 | 100.0 |
Calcium/*metabolism | 4 | 0.0 |
Calcium-Binding Proteins/*analysis | 3 | 23.0 |
Hela Cells | 2 | 0.0 |
Thapsigargin/pharmacology | 2 | 1.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Neoplasm Metastasis/genetics | 3 | 7.0 |
Cattle | 3 | 0.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Child | 2 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Base Sequence | 7 | 0.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Mice, Transgenic | 4 | 0.0 |
Breast Neoplasms/*genetics/pathology | 2 | 0.0 |
Carcinoma, Ductal, Breast/*genetics/pathology | 2 | 7.0 |
Antibodies, Monoclonal | 2 | 0.0 |
*Genes, p16 | 3 | 3.0 |
*S100 Proteins | 8 | 10.0 |
Signal Transduction | 2 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Calcium-Binding Proteins/*metabolism | 3 | 3.0 |
Disease Progression | 4 | 0.0 |
*Nucleoside-Diphosphate Kinase | 2 | 3.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Culture Media, Conditioned | 2 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
S100 Proteins/analysis/*biosynthesis | 2 | 100.0 |
Genetic Vectors | 2 | 0.0 |
Neoplasm Proteins/genetics/*metabolism | 2 | 1.0 |
*Genes, erbB-2 | 2 | 2.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Mice, Nude | 3 | 0.0 |
Transplantation, Heterologous | 3 | 0.0 |
In Vitro | 2 | 0.0 |
Gelatinase A/*biosynthesis | 2 | 22.0 |
Breast Neoplasms/*pathology | 2 | 0.0 |
Gene Expression | 4 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
Periodontal Ligament/cytology/*metabolism | 2 | 22.0 |
Fibroblasts/*metabolism/pathology | 2 | 8.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
